Background and objectives: The aims of the study were to evaluate the utility of neutrophil-to-lymphocyte ratio (NLR) and the systemic immune-inflammation index (SII) as inflammation markers and prognostic factors in patients with known interstitial lung disease secondary to connective tissue diseases (CTD-ILD) compared with idiopathic pulmonary fibrosis (IPF). Materials and Methods: Forty-two patients with known interstitial lung disease (21 with IPF and 21 with CTD-ILD) and 42 control matched healthy patients were included. The NLR was calculated as the absolute neutrophil count divided by the absolute lymphocyte count, and the SII was calculated as follows: SII = platelets × neutrophils/lymphocytes, with the data being obtained from the patients data charts at admission, before any treatment. Results: our hypothesis was that in patients with interstitial lung disease NLR and SII would have higher values compared with patients with CTD-ILD or control healthy patients. The mean NLR value was 3.01 (±1.35) among patients with idiopathic pulmonary fibrosis, and 2.38 (±1.08) among patients with CTD-ILD without significant statistical difference (p = 0.92). There was however a clinically significant statistical difference when compared with the control group, where NLR was 2.00 (±1.05) (p = 0.003). SII values were 619.37 (±329.51) in patients with IPF, 671.55 (±365.73) in CTD-ILD group and 569.73 (±326.67) in healthy subjects (p = 0.13) Conclusions: A mean NLR value of 2.8 and a SII value over 500 in patients with connective diseases can become a marker of pulmonary interstitial involvement. In the context of non-exacerbated interstitial lung disease, NLR and SII have reduced numerical values, without being statistically correlated with prognosis when we compared with patients with connective tissue diseases without exacerbation or with healthy people, the cut off being of 2.4. However subsequent studies in larger patient samples might provide changes in these cut-off values.
The aim of this study was to investigate the concentration level of some major-to-trace elements and toxic minerals and polyphenols (catechin, epicatechin and quercetin) in fruits belonging to different apple cultivars (‘Auriu de Cluj’, ‘Florina’, ‘Generos’, ‘Golden Delicious’, ‘Prima’, ‘Productiv de Cluj’ and ‘Starkrimson’), under specific climate conditions to northwestern Romania. The apple minerals were determined by the inductively coupled plasma mass spectrometry (ICP-MS) and inductively coupled plasma optical emission spectrometry (ICP-OES) after a preliminary, microwave-assisted, acid digestion. The polyphenols were determined by high performance liquid chromatography (HPLC) with MS/MS detection. According to the obtained results, the edible part of the apple contains many minerals with high relative nutritional value (RNV). The major minerals (Na, K, Ca, Mg and P), minor elements (Cu, Fe, Mn, Sr and Zn) and toxic trace elements (Cd, Cr and Pb) were comparatively identified and quantified. It was found that K (31976 mg/kg) was predominant among the major elements, while Fe (3.68 mg/kg) and Cu (3.57 mg/kg) were comparable. The toxic trace metals (Cd, Cr and Pb) were below the limits of detection (0.01, 0.10 and 0.01 mg/kg, respectively) and did not determine any health risk to consumers. The main polyphenols composition (catechin, epicathechin, quercetin) differs slightly among different cultivars. In ‘Idared’ and ‘Jonathan’ cultivars, the investigated polyphenols are in higher quantities comparing to the others. In all investigated apple cultivars, quercetin was proved to be the major polyphenol, followed by epicathechin and catechin. These results suggest that, regarding only the investigated polyphenols, ‘Idared’ and ‘Jonathan’ cultivars have the highest antioxidant character in all investigated genotypes.
Photobiomodulation therapy (PBMT) is an effective treatment modality, which has the significant advantage of enhancing a patient’s quality of life (QoL) by minimising the side effects of oral cancer treatments, as well as assisting in the management of potentially cancerous lesions. It is important to note that the major evidence-based documentation neither considers, nor tackles, the issues related to the impact of PBMT on tumour progression and on the downregulation of cellular proliferation improvement, by identifying the dose- and time-dependency. Moreover, little is known about the risk of this therapy and its safety when it is applied to the tumour, or the impact on the factor of QoL. The review aimed to address the benefits and limitations of PBMT in premalignant oral lesions, as well as the conflicting evidence concerning the relationship between tumour cell proliferation and the applied dose of photonic energy (fluence) in treating oral mucositis induced by head and neck cancer (H&N) treatments. The objective was to appraise the current concept of PBMT safety in the long-term, along with its latent impact on tumour reaction. This review highlighted the gap in the literature and broaden the knowledge of the current clinical evidence-based practice, and effectiveness, of PBMT in H&N oncology patients. As a result, the authors concluded that PBMT is a promising treatment modality. However, due to the heterogeneity of our data, it needs to undergo further testing in well-designed, long-term and randomised controlled trial studies, to evaluate it with diligent and impartial outcomes, and ensure laser irradiation’s safety at the tumour site.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.